A new treatment for EM and ALS
MSALS consortium has been created by biotechnological companies Advancell, Neurotec Pharma and Aromics to develop a new treatment for Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). This project has the support of the Generalitat de Catalunya through the Catalan Government agency ACC1Ó through the program Nuclis d’Innovació Tecnològica.
The general objectives pursued by this project are:
- Validation of genetic biomarkers of efficacy response of the proposed treatment and identify new therapeutic target in MS,
- Conducting a clinical trial in patients with Relapsing-Remitting MS to assess the efficacy and safety of the developed drug and
- Perform preclinical studies to assess the efficacy of the proposed drug in an accepted animal model of ALS.
MSALS also has the clinic coordination of the Hospital Clínic de Barcelona and of the Hospital de la Vall d'Hebron de Barcelona, as well as the collaboration of the University of Barcelona and of the Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.